BACKGROUND: This study evaluated the efficacy of bupropion for relapse prevention in smokers with and without a past history of major depressive disorder. Changes in depressive symptoms were also examined. DESIGN: Data were gathered prospectively from a randomized, double-blind relapse prevention trial of bupropion conducted at five study sites. A total of 784 smokers (54% female, 97% white) were enrolled. Using the Structured Clinical Interview for Depression, 17% of the subjects reported a past history of major depressive disorder at baseline. All subjects received open-label bupropion SR (300 mg/d) for 7 weeks. Subjects abstinent from smoking at the end of 7 weeks (N = 429) were randomized to bupropion SR (300 mg/d) or placebo for the remainder of the year and followed for 1 year off medication. The primary outcome measures were median time to relapse to smoking and the 7-day point-prevalence smoking abstinence rate. Self-reported abstinence from smoking was verified by expired air carbon monoxide. The Beck Depression Inventory was used to assess depressive symptoms at baseline and at weeks 8 and 12. RESULTS:Median time to relapse did not differ by past history of major depressive disorder. Bupropion was associated with higher point-prevalence smoking abstinence at the end of medication compared to placebo (P = .007), independent of a past history of major depressive disorder. Moreover, change in depressive symptoms during the double-blind phase did not differ for those with and without a past history of major depressive disorder. CONCLUSIONS: Extended use of bupropion for relapse prevention is effective for smokers with and without a history of major depression.
RCT Entities:
BACKGROUND: This study evaluated the efficacy of bupropion for relapse prevention in smokers with and without a past history of major depressive disorder. Changes in depressive symptoms were also examined. DESIGN: Data were gathered prospectively from a randomized, double-blind relapse prevention trial of bupropion conducted at five study sites. A total of 784 smokers (54% female, 97% white) were enrolled. Using the Structured Clinical Interview for Depression, 17% of the subjects reported a past history of major depressive disorder at baseline. All subjects received open-label bupropion SR (300 mg/d) for 7 weeks. Subjects abstinent from smoking at the end of 7 weeks (N = 429) were randomized to bupropion SR (300 mg/d) or placebo for the remainder of the year and followed for 1 year off medication. The primary outcome measures were median time to relapse to smoking and the 7-day point-prevalence smoking abstinence rate. Self-reported abstinence from smoking was verified by expired air carbon monoxide. The Beck Depression Inventory was used to assess depressive symptoms at baseline and at weeks 8 and 12. RESULTS: Median time to relapse did not differ by past history of major depressive disorder. Bupropion was associated with higher point-prevalence smoking abstinence at the end of medication compared to placebo (P = .007), independent of a past history of major depressive disorder. Moreover, change in depressive symptoms during the double-blind phase did not differ for those with and without a past history of major depressive disorder. CONCLUSIONS: Extended use of bupropion for relapse prevention is effective for smokers with and without a history of major depression.
Authors: J T Hays; R D Hurt; N A Rigotti; R Niaura; D Gonzales; M J Durcan; D P Sachs; T D Wolter; A S Buist; J A Johnston; J D White Journal: Ann Intern Med Date: 2001-09-18 Impact factor: 25.391
Authors: H S Thorsteinsson; J C Gillin; C A Patten; S Golshan; L D Sutton; S Drummond; C P Clark; J Kelsoe; M Rapaport Journal: Neuropsychopharmacology Date: 2001-04 Impact factor: 7.853
Authors: Allison J Carroll; Amanda R Mathew; Frank T Leone; E Paul Wileyto; Andrew Miele; Robert A Schnoll; Brian Hitsman Journal: Nicotine Tob Res Date: 2020-01-27 Impact factor: 4.244
Authors: Brian Hitsman; George D Papandonatos; Dennis E McChargue; Andrew DeMott; María José Herrera; Bonnie Spring; Belinda Borrelli; Raymond Niaura Journal: Addiction Date: 2013-02 Impact factor: 6.526
Authors: Sharon M Hall; Gary L Humfleet; Ricardo F Muñoz; Victor I Reus; Judith J Prochaska; Julie A Robbins Journal: Am J Public Health Date: 2011-06-08 Impact factor: 9.308
Authors: Richard A Brown; Raymond Niaura; Elizabeth E Lloyd-Richardson; David R Strong; Christopher W Kahler; Ana M Abrantes; David Abrams; Ivan W Miller Journal: Nicotine Tob Res Date: 2007-07 Impact factor: 4.244
Authors: Sharon M Hall; Gary L Humfleet; Ricardo F Muñoz; Victor I Reus; Julie A Robbins; Judith J Prochaska Journal: Addiction Date: 2009-04-09 Impact factor: 6.526